Iguratimod
(T-614) is a novel disease modifying anti-rheumatic drug (DMARD). Iguratimod
is characterized by inhibitory effects on immunoglobulin production in B cells
as well as inhibiting cytokine production. Its' mode of action comes by suppression of nuclear factor kappa B
(NF-kB) activation. As I have already written this before, please look for the
links below. 2012 there had been three studies, 2013 one study at the EULAR Meeting
in Madrid (a study by a Chinese group).
There has
only been on study at the ACR 2013 Meeting. Daisuke Kobayashi and colleagues
published the following study [#1422]: “Efficacy and Safety Of a Novel
Disease-Modifying Antirheumatic Drug, Iguratimod, As Add-On Therapy For
Patients With Rheumatoid Arthritis.” The study has been small (N=26). Conclusion:
“Iguratimod is effective as add-on therapy in RA patients who have shown
inadequate responses to previous therapy, although caution is necessary
regarding hemorrhagic tendency in patients receiving warfarin, which was cautioned
by Ministry of Health, Labour and Welfare of Japan.”
I think
iguratimod is indeed a promising candidate for treatment of active rheumatoid
arthritis and might become a needed alternative in the conventional
(traditional) DMARD class. I wished the sponsor would press more for results,
also for studies, which would result in an appearance on the world market.
Link:
Iguratimod
at the EULAR Meeting 2012 http://rheumatologe.blogspot.de/2012/06/iguratimod-at-eular-2012.html
Iguratimod
at the EULAR Meeting 2013 http://rheumatologe.blogspot.de/2013/06/iguratimod-at-eular-2013.html
No comments:
Post a Comment